BR112015029969A2 - tratamento de câncer usando moduladores de isoformas quinase pi3 - Google Patents
tratamento de câncer usando moduladores de isoformas quinase pi3Info
- Publication number
- BR112015029969A2 BR112015029969A2 BR112015029969A BR112015029969A BR112015029969A2 BR 112015029969 A2 BR112015029969 A2 BR 112015029969A2 BR 112015029969 A BR112015029969 A BR 112015029969A BR 112015029969 A BR112015029969 A BR 112015029969A BR 112015029969 A2 BR112015029969 A2 BR 112015029969A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer treatment
- kinase modulators
- isoform
- isoform kinase
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
resumo tratamento de câncer usando moduladores de isoformas quinase pi3 a invenção se refere a métodos, kits e composições farmacêuticas que incluem um inibidor de quinase pi3 para o tratamento de câncer ou doenças hematológicas. 1/1
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361829168P | 2013-05-30 | 2013-05-30 | |
US201361836088P | 2013-06-17 | 2013-06-17 | |
US201361863365P | 2013-08-07 | 2013-08-07 | |
US201361888454P | 2013-10-08 | 2013-10-08 | |
PCT/US2013/067929 WO2014071109A1 (en) | 2012-11-01 | 2013-11-01 | Treatment of cancers using pi3 kinase isoform modulators |
US201461991414P | 2014-05-09 | 2014-05-09 | |
PCT/US2014/040337 WO2014194254A1 (en) | 2013-05-30 | 2014-05-30 | Treatment of cancers using pi3 kinase isoform modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015029969A2 true BR112015029969A2 (pt) | 2017-07-25 |
Family
ID=51989439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015029969A BR112015029969A2 (pt) | 2013-05-30 | 2014-05-30 | tratamento de câncer usando moduladores de isoformas quinase pi3 |
Country Status (17)
Country | Link |
---|---|
US (4) | US20160113932A1 (pt) |
EP (2) | EP3811974A1 (pt) |
JP (2) | JP6556702B2 (pt) |
KR (1) | KR20160013204A (pt) |
CN (1) | CN105682658B (pt) |
AU (1) | AU2014273946B2 (pt) |
BR (1) | BR112015029969A2 (pt) |
CA (1) | CA2914284A1 (pt) |
DK (1) | DK3003309T3 (pt) |
ES (1) | ES2834638T3 (pt) |
HK (1) | HK1219870A1 (pt) |
IL (2) | IL242826B (pt) |
MX (1) | MX2015016277A (pt) |
RU (2) | RU2705204C2 (pt) |
SG (2) | SG10201709926VA (pt) |
WO (1) | WO2014194254A1 (pt) |
ZA (1) | ZA201508711B (pt) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009088990A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
JP5746172B2 (ja) | 2009-08-20 | 2015-07-08 | カルス セラピューティクス リミテッド | ホスホイノシチド3−キナーゼ阻害剤としての三環式複素環化合物 |
AU2011260961B9 (en) | 2010-05-31 | 2015-02-26 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
CA3154024C (en) | 2010-06-03 | 2024-02-27 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
PT2786996T (pt) | 2011-11-29 | 2016-11-07 | Ono Pharmaceutical Co | Cloridrato de derivado de purinona |
US9296753B2 (en) | 2012-06-04 | 2016-03-29 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
CN104854107A (zh) | 2012-11-15 | 2015-08-19 | 药品循环公司 | 作为激酶抑制剂的吡咯并嘧啶化合物 |
CA2906166C (en) | 2013-03-15 | 2023-03-14 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
US20160303135A1 (en) | 2013-12-06 | 2016-10-20 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2015116729A2 (en) * | 2014-01-28 | 2015-08-06 | Emergent Product Development Seattle, Llc | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
WO2015146159A1 (en) | 2014-03-25 | 2015-10-01 | Ono Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
PL3157527T3 (pl) * | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
WO2016022942A1 (en) | 2014-08-07 | 2016-02-11 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
DK3179991T3 (da) * | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
SG11201707122QA (en) | 2015-03-03 | 2017-09-28 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
JP6750613B2 (ja) | 2015-04-09 | 2020-09-02 | 小野薬品工業株式会社 | プリノン誘導体の製造方法 |
JP6823587B2 (ja) | 2015-04-13 | 2021-02-03 | 第一三共株式会社 | Mdm2阻害剤とbtk阻害剤との併用治療法 |
JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム,インコーポレイティド | リンパ腫を処置するためのezh2阻害剤 |
JP6785804B2 (ja) * | 2015-06-23 | 2020-11-18 | ギリアド サイエンシズ, インコーポレイテッド | B細胞悪性腫瘍を治療するための組合せ療法 |
GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
CN108601838A (zh) * | 2015-09-21 | 2018-09-28 | 意大利癌症研究基金会分子肿瘤学研究所(Ifom) | 对抗血液癌症的新治疗策略 |
US20180282818A1 (en) * | 2015-10-08 | 2018-10-04 | The Wistar Institute Of Anatomy And Biology | Therapeutic Cancer Treatments Based on TP53 Gene Mutations |
WO2017079003A1 (en) * | 2015-11-03 | 2017-05-11 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating blood cancers, and compositions and methods thereof |
CN108699061B (zh) * | 2015-11-16 | 2022-07-05 | 纽弗姆制药有限公司 | 用于治疗血液恶性肿瘤、炎症和自身免疫性疾病的氘代化合物 |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
WO2018076060A1 (en) | 2016-10-26 | 2018-05-03 | Genea Ip Holdings Pty Ltd | Improved generation of muscle lineage cells and therapeutic uses thereof |
EP3538102A4 (en) * | 2016-11-10 | 2020-06-24 | Memorial Sloan-Kettering Cancer Center | INHIBITATION OF KMT2D FOR TREATING CANCER |
CN110225980B (zh) | 2016-11-21 | 2023-01-06 | 纳米线科技公司 | 化学组合物及其使用方法 |
EA201991355A1 (ru) * | 2016-12-07 | 2019-11-29 | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
AU2018246257B2 (en) * | 2017-03-30 | 2022-05-12 | Merck Patent Gmbh | Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol |
HUE061898T2 (hu) | 2017-09-08 | 2023-08-28 | Beigene Ltd | Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok |
CA3099909A1 (en) | 2018-05-14 | 2019-11-21 | Nanostring Technologies, Inc. | Chemical compositions and methods of using same |
JP2022553820A (ja) | 2019-11-05 | 2022-12-26 | アッヴィ・インコーポレイテッド | 骨髄線維症及びmpn関連障害をナビトクラクスで処置する際に使用するための投与レジメン |
US11648255B2 (en) * | 2020-07-06 | 2023-05-16 | Masarykova Univerzita | Inhibitors for treatment of hematological malignancies |
EP4185279A4 (en) * | 2020-07-24 | 2024-05-01 | Secura Bio Inc | TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS |
US20230010803A1 (en) * | 2021-06-30 | 2023-01-12 | Janssen Pharmaceutica Nv | Treatments for diffuse large b-cell lymphoma |
Family Cites Families (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
EP1134293A3 (en) | 1992-03-04 | 2004-01-07 | The Regents of The University of California | Comparative genomic hybridization (CGH) |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
WO1996033172A1 (en) | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
CA2224381A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
SK21499A3 (en) | 1996-08-23 | 2000-05-16 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
BR9714266A (pt) | 1997-01-06 | 2000-04-18 | Pfizer | Derivados de sulfona cìclicos. |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
PL335027A1 (en) | 1997-02-03 | 2000-03-27 | Pfizer Prod Inc | Derivatives of arylsulphonylamino hydroxamic acid |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
AU722784B2 (en) | 1997-02-11 | 2000-08-10 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6432970B2 (en) | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20070021493A1 (en) | 1999-09-16 | 2007-01-25 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
AU780846B2 (en) | 1999-09-16 | 2005-04-21 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
DE60028411T2 (de) | 1999-10-13 | 2007-01-04 | Johns Hopkins University School Of Medicine | Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon |
ATE324876T1 (de) | 1999-10-14 | 2006-06-15 | Curis Inc | VERMITTLER VON ßHEDGEHOGß ÜBERMITTELNDEN BAHNEN, DAZUGEHÖRIGE ZUSAMMENETZUNGEN UND VERWENDUNGEN |
WO2001042507A1 (en) | 1999-12-09 | 2001-06-14 | Advanced Research & Technology Institute | Fluorescent in situ rt-pcr |
IL133809A0 (en) | 1999-12-30 | 2001-04-30 | Yeda Res & Dev | Steroidal alkaloids and pharmaceutical compositions comprising them |
ES2250377T5 (es) | 2000-03-30 | 2010-04-06 | Curis, Inc. | Moleculas organicas pequeñas reguladoras de la proliferacion celular. |
JP4808365B2 (ja) | 2001-03-02 | 2011-11-02 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Pcr法 |
EA007339B1 (ru) | 2001-07-27 | 2006-08-25 | Кьюэрис, Инк. | Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ |
CA2458533C (en) | 2001-10-09 | 2011-01-04 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
US20030113828A1 (en) | 2001-11-09 | 2003-06-19 | Ginsberg Mark H. | Compositions and methods for modulating Syk function |
US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
WO2003088970A2 (en) | 2002-04-22 | 2003-10-30 | Johns Hopkins University School Of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
JP2006512313A (ja) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
FR2850022B1 (fr) | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
AU2004257167B2 (en) | 2003-07-03 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
US20080118493A1 (en) | 2003-07-15 | 2008-05-22 | Beachy Philip A | Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity |
US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
WO2005032343A2 (en) | 2003-10-01 | 2005-04-14 | The Johns Hopkins University | Hedgehog signaling in prostate regeneration neoplasia and metastasis |
WO2005042700A2 (en) | 2003-10-20 | 2005-05-12 | The Johns Hopkins University | Use of hedgehog pathway inhibitors in small-cell lung cancer |
US20050267059A1 (en) | 2003-11-14 | 2005-12-01 | Diana Beardsley | Syk-targeted nucleic acid interference |
US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
US8057815B2 (en) | 2004-04-19 | 2011-11-15 | Portola Pharmaceuticals, Inc. | Methods of treatment with Syk inhibitors |
DK1745041T3 (da) | 2004-04-30 | 2012-09-24 | Genentech Inc | Quinoxalin-inhibitorer af hedgehog-signaleringsvejen |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
CN102241727B (zh) | 2004-08-27 | 2015-03-25 | 无限药品股份有限公司 | 环杷明类似物及其使用方法 |
SI1789390T1 (sl) | 2004-09-02 | 2012-05-31 | Genentech Inc | Piridilni inhibitorji hedgehog signalizacije |
BRPI0517253A (pt) | 2004-10-28 | 2008-10-07 | Irm Llc | compostos e composições como moduladores de trajetória de ouriço |
KR100917511B1 (ko) | 2005-02-28 | 2009-09-16 | 니뽄 다바코 산교 가부시키가이샤 | Syk 저해 활성을 갖는 신규한 아미노피리딘 화합물 |
US20090156611A1 (en) | 2005-11-11 | 2009-06-18 | Licentia Ltd. | Mammalian hedgehog signaling modulators |
CA2629814C (en) | 2005-11-14 | 2013-12-31 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
CN101405001A (zh) | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
CA2648196A1 (en) | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders |
UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
ES2542344T3 (es) | 2006-05-09 | 2015-08-04 | Novaremed Ltd. | Uso de inhibidores de tirosina cinasa Syk para el tratamiento de trastornos proliferativos celulares |
CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
MY181496A (en) | 2006-10-31 | 2020-12-23 | Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services | Smoothened polypeptides and methods of use |
KR20090090383A (ko) | 2006-12-14 | 2009-08-25 | 다이이찌 산쿄 가부시키가이샤 | 이미다조티아졸 유도체 |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
CN101675054B (zh) | 2007-03-07 | 2014-05-14 | 无限发现股份有限公司 | 环杷明内酰胺类似物及其使用方法 |
AU2008223355B2 (en) | 2007-03-07 | 2014-03-20 | Infinity Discovery, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
JP5577104B2 (ja) | 2007-03-14 | 2014-08-20 | エクセリクシス パテント カンパニー エルエルシー | ヘッジホッグ経路の阻害剤 |
JP5550352B2 (ja) | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
US20090054517A1 (en) | 2007-04-20 | 2009-02-26 | Lubahn Dennis B | Phytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment |
WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
BRPI0820856A2 (pt) | 2007-12-13 | 2019-05-14 | Siena Bhiotech.S.P.A. | anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009088990A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
CN101910081B (zh) | 2008-01-10 | 2012-10-10 | 旭硝子株式会社 | 玻璃、发光装置用被覆材料及发光装置 |
WO2009089598A2 (en) | 2008-01-18 | 2009-07-23 | Katholieke Universiteit Leuven | Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
FR2929851B1 (fr) | 2008-04-09 | 2012-11-30 | Centre Nat Rech Scient | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules |
PT2323993E (pt) | 2008-04-16 | 2015-10-12 | Portola Pharm Inc | 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak |
CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
WO2010051550A1 (en) | 2008-10-31 | 2010-05-06 | University Of Rochester | Methods of diagnosing and treating fibrosis |
AU2009313878B2 (en) * | 2008-11-13 | 2016-01-07 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
JP5696052B2 (ja) | 2008-12-08 | 2015-04-08 | ギリアード コネチカット, インコーポレイテッド | イミダゾピラジンsyk阻害剤 |
EP2376481B1 (en) | 2009-01-13 | 2013-08-07 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase |
CA2751563A1 (en) | 2009-02-04 | 2010-08-12 | Jelena Mann | Methods of inhibiting fibrogenesis and treating fibrotic disease |
CA2772371A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
US8173650B2 (en) | 2009-05-27 | 2012-05-08 | Genentech, Inc. | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
WO2010147898A2 (en) | 2009-06-15 | 2010-12-23 | Rigel Pharmaceuticals, Inc. | Small molecule inhibitors of spleen tyrosine kinase (syk) |
US8722692B2 (en) | 2009-07-30 | 2014-05-13 | Jianwei Che | Compounds and compositions as Syk kinase inhibitors |
TW201105669A (en) | 2009-07-30 | 2011-02-16 | Irm Llc | Compounds and compositions as Syk kinase inhibitors |
CA2775942A1 (en) | 2009-09-29 | 2011-04-07 | Xcovery Holding Company Llc | Pi3k (delta) selective inhibitors |
WO2011075560A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
SG181803A1 (en) | 2009-12-17 | 2012-07-30 | Merck Sharp & Dohme | Aminopyrimidines as syk inhibitors |
ES2545616T3 (es) | 2009-12-23 | 2015-09-14 | Takeda Pharmaceutical Company Limited | Pirrolidinonas heteroaromáticas condensadas como inhibidores de SYK |
WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
CA3154024C (en) * | 2010-06-03 | 2024-02-27 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma |
EP2579878A1 (en) * | 2010-06-11 | 2013-04-17 | Gilead Calistoga LLC | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
US20130195843A1 (en) | 2010-06-23 | 2013-08-01 | British Columbia Cancer Agency Branch | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof |
PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US8846928B2 (en) | 2010-11-01 | 2014-09-30 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
NZ612909A (en) * | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
JP5934782B2 (ja) | 2011-05-04 | 2016-06-15 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | アミノ−ピリジン含有脾臓チロシンキナーゼ(Syk)阻害薬 |
TWI565709B (zh) | 2011-07-19 | 2017-01-11 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
HRP20212021T1 (hr) * | 2011-07-19 | 2022-04-01 | Merck Sharp & Dohme B.V. | 4-IMIDAZOPIRIDAZIN-1-iL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI KAO INHIBITORI BTK |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
CN110801454A (zh) * | 2011-10-19 | 2020-02-18 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的用途 |
HUE034591T2 (en) | 2012-07-04 | 2018-02-28 | Rhizen Pharmaceuticals S A | Selective PI3K delta inhibitors |
MX2015001081A (es) * | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
CN105102000B (zh) * | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
-
2014
- 2014-05-30 EP EP20194640.7A patent/EP3811974A1/en not_active Withdrawn
- 2014-05-30 US US14/894,854 patent/US20160113932A1/en not_active Abandoned
- 2014-05-30 US US14/292,475 patent/US20140377258A1/en not_active Abandoned
- 2014-05-30 ES ES14804451T patent/ES2834638T3/es active Active
- 2014-05-30 AU AU2014273946A patent/AU2014273946B2/en active Active
- 2014-05-30 EP EP14804451.4A patent/EP3003309B1/en active Active
- 2014-05-30 KR KR1020157036896A patent/KR20160013204A/ko not_active Application Discontinuation
- 2014-05-30 DK DK14804451.4T patent/DK3003309T3/da active
- 2014-05-30 WO PCT/US2014/040337 patent/WO2014194254A1/en active Application Filing
- 2014-05-30 CA CA2914284A patent/CA2914284A1/en not_active Abandoned
- 2014-05-30 SG SG10201709926VA patent/SG10201709926VA/en unknown
- 2014-05-30 JP JP2016517058A patent/JP6556702B2/ja active Active
- 2014-05-30 MX MX2015016277A patent/MX2015016277A/es active IP Right Grant
- 2014-05-30 BR BR112015029969A patent/BR112015029969A2/pt not_active Application Discontinuation
- 2014-05-30 RU RU2015156069A patent/RU2705204C2/ru active
- 2014-05-30 SG SG11201509842SA patent/SG11201509842SA/en unknown
- 2014-05-30 CN CN201480043018.8A patent/CN105682658B/zh active Active
- 2014-05-30 RU RU2019134551A patent/RU2019134551A/ru unknown
-
2015
- 2015-11-26 ZA ZA2015/08711A patent/ZA201508711B/en unknown
- 2015-11-29 IL IL24282615A patent/IL242826B/en active IP Right Grant
-
2016
- 2016-06-24 HK HK16107388.7A patent/HK1219870A1/zh unknown
-
2017
- 2017-01-31 US US15/421,020 patent/US20170360795A1/en not_active Abandoned
-
2019
- 2019-07-10 JP JP2019128045A patent/JP6870185B2/ja active Active
- 2019-09-24 IL IL26960119A patent/IL269601A/en unknown
-
2022
- 2022-12-12 US US18/064,880 patent/US20230364097A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
CO6551721A2 (es) | Moduladores de cinasa novedosos | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
BR112017009648A2 (pt) | composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto. | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
BR112016007467A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
BR112015023760A2 (pt) | compostos e composições terapêuticas | |
BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
BR112016025470A2 (pt) | ?hdl terapêutico? | |
BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
CR20160047A (es) | Inhibidores de rorc2 y sus métodos de uso | |
EA201690159A1 (ru) | Способы и композиции для лечения рака | |
BR112013011441A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
EA031679B9 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
BR112017024163A2 (pt) | compostos bicíclicos | |
BR112017008867A2 (pt) | inibidores de proteína quinases | |
EA201691493A1 (ru) | Замещенные n-арилпиридиноны | |
BR112017019154A2 (pt) | uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |